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Pharmacy and therapeutics committees commonly cite a
lack of generalizability as a reason for not incorporating cost-
effectiveness information into decision making. To address
this concern, many committees undertake site-specific eco-
nomic evaluations, which are often limited by small sample
sizes and nonrandomized designs. We show how 2 comple-
mentary approacheswere used tominimize these limitations
in an economic evaluation of abciximab at 1 institution.
Using a propensity score methodology, we selected patients
who did not receive abciximab for the comparison cohort.
Then, we adopted a Bayesian, hierarchical, random-effects
model to integrate site-specific and clinical trial data.We ap-
plied the posterior distributions of effectiveness with local
cost data in a traditional decision-analytic model. In 74% of
the simulations, abciximab was cost-effective at 1 institution
at the $50,000per life year saved threshold, assuming a 50:50
split of patients undergoing coronary stenting and
angioplasty. Among patients undergoing coronary stenting,
the cost-effectiveness ratio of the addition of abciximab was
at or below the $50,000per life year saved threshold in 66.0%
of the simulations. Key words: Bayesian analysis; cost-
effectiveness; decision making; formulary decision making;
Monte Carlo simulation.
Randomized clinical trials (RCTs) are thewidely ac-cepted gold-standard design for conducting clini-
cal efficacy research. In recent years, cost-effectiveness
analyses (CEAs) increasingly have been conducted
alongside RCTs to take advantage of theirmethodologi-
cal rigor.1,2However, decisionmakers inhealth care fre-
quently state concerns that patients, providers, prac-
tice patterns, and costs are different at their respective
institutions. Thus, they claim that they cannot directly
apply the results of CEAs based on data from RCTs
when deciding on the local adoption of an interven-
tion. In response to these issues, institutions or man-
aged care plans may undertake site-specific or plan-
specific economic evaluations to assess whether an in-
tervention is cost-effective in their settings.
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However, there are 2 major problems that arise in
many local CEAs: an inability to randomize and insuf-
ficient statistical power. If the treatment inquestionhas
already been deemed to be safe and efficacious by the
US Food and Drug Administration, institutional re-
view boards will often not approve randomized de-
signs to study the effectiveness of the drug locally, even
when thepopulation of patients is argued todiffer from
the patients enrolled in the RCTs. Therefore, analysts
must rely onnonrandomizeddesigns to evaluate the ef-
fectiveness of the drug as used in their institutions.
With regard to statistical power, a sufficient sample size
for detecting a statistical difference for CEAs is usually
considerably larger than that required for health out-
comes.3 Furthermore, it is likely that local institutions
will be treating fewer patients than were recruited to
the RCTs, raising concern over the power to detect true
differences, even in the clinical effect of treatment.4 In
these cases, differences in health outcomes (the de-
nominator of the cost-effectiveness ratio) are not statis-
tically different from zero, and the calculation of confi-
dence intervals for incremental cost-effectiveness
ratios (ICERs) is problematic.5–7
STUDY AIM
The aim of this article is to provide a real-world ex-
ample of how the use of 2 complementary and innova-
tive approaches can minimize limitations associated
with relatively small, nonrandomized, site-specific
CEAs. First, we used a propensity score methodology
to select appropriate patients for a local comparison co-
hort. Second, we adopted a Bayesian statistical ap-
proach to derive institution-specific cost-effectiveness
estimates on the basis of a combination of local and
RCT data.
We expand on a previously conducted CEA of
abciximab, a drug used in conjunction with per-
cutaneous coronary revascularization procedures to
prevent ischemic complications such as death, myo-
cardial infarction (MI), and subsequent revasculariza-
tion.8 In 1995, the pharmacy and therapeutics commit-
tee at the University of Maryland Medical System
(UMMS) added abciximab to the formulary on a provi-
sional basis, under thepremise that its formal inclusion
would be reevaluated at the conclusion of the CEA. At
that time, only 1 trial, the EPIC trial, had been pub-
lished regarding the efficacy of abciximab.9 The trial
was conducted on high-risk patients undergoing bal-
loon angioplasty, but many of the patients at UMMS
were receiving abciximab in conjunction with coro-
nary stenting, and many patients at UMMS would not
havemet the trial’s inclusion criteria because theywere
at a lower risk for ischemic events. Therefore, on intro-
duction of abciximab,many questions existed about its
real-world effectiveness outside of clinical trial set-
tings. While the local study was being conducted, the
results of EPILOG and EPISTENT were published,
thereby minimizing concerns regarding the effective-
ness of the drug in lower risk patients and in those un-
dergoing coronary stenting. However, it was still un-
known whether patients receiving abciximab outside
of clinical trial settings were experiencing similar out-
comes to those in the trials. Since that time,muchmore
information supporting the effectiveness of abciximab
has been published. Therefore, the analyses described
herein should serve more as a historical example of
how these methods might have been used rather than
an attempt to quantify the cost-effectiveness of
abciximab in contemporary practice.
METHODS
Construction of Comparison Cohort
In nonrandomized study designs, differences be-
tween treated and nontreated patients are likely to pro-
duce biased estimates of treatment effects and cost dif-
ferences. Tominimize these biases in an analysis of the
UMMS data, we used a propensity score methodology
to identify patients not treated with abciximab who
were similar to abciximab-treated patients on a wide
range of observed covariates.10Matching using propen-
sity scores has been shown to reduce bias to a greater
extent than other matching techniques when a large
number of covariates are considered.11 Further, esti-
matedpropensity scores are superior to truepropensity
scores at eliminating bias because the method also re-
moves biases that occur because of chance.11–14We pre-
fer this matching technique over multivariable regres-
sion because it allows one to determine whether there
is sufficient overlap between the treatment groups in
terms of covariates associated with treatment.15 If the 2
cohorts are dissimilar, adjusting for differences in a
multivariable framework is likely to provide biased re-
sults because computations are based on linear (or
other higher order) extrapolations of the covariates.
We estimated propensity scores using logistic re-
gression to predict treatment with abciximab (A = 1).
Independent variables consisted of patients’ demo-
graphic characteristics (gender, age [< or ≥ 65 years]),
previous procedures (bypass surgery, percutaneous
transluminal coronary angioplasty [PTCA], stent), car-
diovascular risk factors (diabetes mellitus, hyper-
lipidemia, hypertension, and congestive heart failure),
procedure-related variables (indication for procedure,
 
PTCAv. stenting), angiographic characteristics (Ameri-
canCollegeofCardiologyandAmericanHeartAssocia-
tion morphology scores,16 multivessel disease, pres-
ence of intracoronary thrombus), and level of care
(intensive care unit or cardiac care unit). We used the
propensity score matching technique described by
Rosenbaum and Rubin17 to construct the untreated co-
hort. For each abciximab-treated patient, a patient who
wasnot treatedwith abciximabwith the closest (higher
or lower) propensity score was chosen for inclusion in
the comparison cohort. The propensity score for an in-
dividual patient (i = 1, 2, 3, . . . n) was defined as the
conditionalprobability of being treatedwith abciximab
(AI = 1), given a patient’s vector of observed covariates,
xI:
e(xi) = pr(Ai = 1 | Xi = xi),
where the treatment (AI) and the covariates (Xi) are as-
sumed to be independent:
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To assess the capacity of the propensity score meth-
odology in constructing 2 comparable cohorts, descrip-
tive statistics were computed, and covariates were
compared using chi-square tests for dichotomous vari-
ables and t tests for continuous variables.
Estimation of Treatment Effects
The results of 3 large RCTs of abciximab have been
reported. The EPIC trial was the 1st large-scale RCT to
assess the efficacy of abciximab in high-risk patients
undergoing balloon angioplasty (PTCA) or ather-
ectomy.9 This study was followed by a 2nd large RCT,
EPILOG, to determine if abciximab would also be effi-
cacious in a lower risk population.18 Both studies used
a similar primary endpoint: a composite endpoint of
death, nonfatal MI, and the need for urgent
revascularization at 30 days and 6months of followup.
Both studies demonstrated a beneficial effect of
abciximab (35% and 54% relative reductions in the
composite endpoint). The 3rd large trial was under-
taken to assess the efficacy of abciximab in a broad
range of patients undergoing coronary stenting.19 De-
spite previous trials showing an approximate 20% to
30% relative reduction in ischemic events with stent-
ing in comparison to balloon angioplasty,20,21 the
addition of abciximab to stenting was superior to
both stenting alone and angioplasty plus abciximab
(51% and 23% relative reductions in the composite
endpoint).
We examined the effect of abciximab on the inci-
dence of death and nonfatal MI at 6 months of follow-
up. Although event rates would have been greater, the
effect of abciximab on the rate of revascularization pro-
cedures was not considered as a health outcome to
avoid double counting in the ICER and because there is
insufficient evidence to model how the need for a sub-
sequent revascularization procedure affects life expec-
tancy. The effect of reduced revascularization rateswas
accounted for in the calculation of the numerator (total
costs at 6 months).
Bayesian Model
The Bayesian paradigm is well suited to informing
decision makers about the cost-effectiveness of medi-
cal therapies. It canbedesigned to incorporatemultiple
sources of information to predict the probability that a
medical therapy is cost-effective. Our approach to inte-
grate data from the clinical trials with our local data
was to employ aBayesian, hierarchical, random-effects
model. A similar approach has been advocated for con-
ducting meta-analyses for clinical trials.22,23 We chose
to use a random-effects specification because it allows
one tomodel a probability for the outcomeof each indi-
vidual data source whereby the joint distribution is in-
dependent of the order in which the data sources are
analyzed. The random-effects approach is based on 2
assumptions. First, the clinical trial data and the local
data are exchangeable.24,25 This simply means that it is
not possible to know beforehand which trials (or local
data) will have high or low event rates. The 2nd as-
sumption is that there is a distribution that represents
all possible treatment effects across various settings.24
Thus, we assumed that event rates for death and
nonfatal MI (within procedures) are similar across
RCTs and at UMMS. This assumption can be consid-
ered as a middle ground between the extreme assump-
tions of “equivalence” and “complete independ-
ence.”25 The model is considered hierarchical in that
there are 3 levels of statistical relationships beingmod-
eled: the individual patient, the individual study, and
the population of possible studies. Specifically, the hi-
erarchical model assumes that patients in each study
are exchangeable in that they all are assumed to have
the same probability of having an event (without other
information). At the level of the individual studies,
each study has certain characteristics that make it dis-
tinct from the other studies. Each study can be thought
of as having its owndistribution of possible results, but
only 1 draw from that distribution is observed. Finally,
 
there is a distribution of results from all possible trials
of the drug that we are attempting to model.
The hierarchical model was used to estimate poste-
rior probabilities for death andMI at 6months for 4 pa-
tient subgroups: patients undergoing PTCA (or
atherectomy) with or without abciximab and patients
undergoing stenting with or without abciximab. All
Bayesian analyses were conducted using WinBUGS,26
a publicly availableWindows-based software package.
The code for the base case model is included in the
Appendix.
The number of events (death or MI), ri, for the ith
study for each of I studies is modeled as a binomial
variable:
ri ~ binomial(pi, ni),
where ni is the number of patients in the ith study, and
pi is theprobability of adeathorMI in the ith study.The
event probability pi is modeled as
logit(pi) ~ normal(logit[θ], σ
2),
where θ is the probability of an adverse event (death or
nonfatalMI) amongall possible trials, andσ2 is the vari-
ance in event probabilities between different trials on
an inverse logit scale.
For this hierarchical model, the parameters (logit[θ]
and σ2) used to specify the distribution of local event
probabilities (pi) also need to be assigned distributions,
referred to as hyperpriors. Hyperprior distributions,
like all prior distributions, can be assigned to be very
flexible or noninformative, so that even very few data
dominate the posterior distribution. Because the num-
ber of studies in this examplewas small, thewide range
of values allowed by noninformative hyperpriors for
logit(θ) and for σ2 led to unrealistic posterior distribu-
tions that included event probabilities up to 100%. To
minimize the impact of these extreme estimates on the
results, the hyperprior distributions for logit(θ) and σ2
were assigned values that still allowed the posterior
distribution to take on a wide range of event probabili-
ties, but not so high that theywere consideredunrealis-
tic. Event probabilities as high as 15% for death and
31% for nonfatal MI were assumed to be very unlikely
and were chosen as conservative upper limits in the
base case. No lower limitswere assigned.Additionally,
σ2 wasmodeled as 1/σ2 ~ γ(2, 2), which still allows for a
reasonably wide range in variance from trial to trial
while restricting the probability of extreme variance,
which would not have been realistic. This eliminated
the possibility of very large differences in event proba-
bilities between clinical trials, an assumption impossi-
ble to test without more trials. However, our limited
data suggest this to be a reasonable assumption.
Cost-Effectiveness Model
A decision-analytic model was constructed in
Microsoft Excel to estimate the cost per life year saved
(LYS) among patients treated with abciximab. The de-
cision model is shown in Figure 1. The Bayesian ran-
dom-effects model was used to compute posterior dis-
tributions for the incidence of events in each treatment
and procedure group.Means,medians, and 95%credi-
ble intervals for eachof theposterior distributionswere
computed on the basis of 2000 iterations after a “burn-
in” of 5000 iterations. Excluding iterations from the
burn-in period is necessary to avoid biased results that
would occur from using iterations from the Markov
chainMonte Carlo (MCMC) sampling algorithm before
it had converged to the equilibrium distribution. The
posterior distributions consisting of 2000 iterations
Die
MI
Live
Stent
Die
MI
Live
PTCA
Abciximab
Die
MI
Live
Stent
Die
MI
Live
PTCA
No Abciximab
Figure 1 Decision tree.
Note:MI =myocardial infarction; PTCA= percutaneous transluminal cor-
onary angioplasty.
 
were integrated into the final branches of the decision
tree for subsequent Monte Carlo simulation.
From a clinical perspective, some patients have cor-
onary lesions that are suitable only for coronary
angioplasty, and some patients have coronary lesions
that are suitable for either angioplasty or stenting.27
Thus, 4 comparisons of various treatment combina-
tions were relevant:
• abciximab v. no abciximab (with a 50:50 split between
PTCA and stenting),
• abciximab and angioplasty v. angioplasty alone,
• abciximab and stenting v. stenting alone, and
• abciximab and angioplasty v. stenting alone.
We assumed that treatment with abciximab or
stentingwouldnot incrementally affect life expectancy
beyond the 1st 6months of followup. Therefore, analo-
gous estimates of life expectancy for each outcome
were assigned for each treatment group. Patients who
were event free during the 6-month followup period
were assumed tohaveanaverage, undiscounted life ex-
pectancy of 20 years, and those who experienced
nonfatal MIs were assumed to have an average,
undiscounted life expectancy of 15 years.28 For the fi-
nal analyses, life expectancies were discounted at 5%
per year.
Cost estimates were based on cumulative 6-month
charge data collected at UMMS for patients treated
with and without abciximab. Charges were converted
to costs using cost-to-charge ratios and were converted
to 1998 US dollars.8 We assumed that costs after the 6-
month followupperiodwouldbe equivalent for eachof
the treatments. Therefore, we simply applied local,
mean 6-month costs to each of the outcomes in the de-
cision tree. We used Monte Carlo simulation to esti-
mate the expected values for each treatment option.
Distributions for the resultant ICERs were used to esti-
mate the overall, joint uncertainty in the model. One
thousand simulations were run for each of the 4 treat-
ment comparisons. For the base case model, we con-
structeda scatterplot of thedifferences in costs andLYS
to visually display variability in the results.We also re-
port the proportion of ICERs estimated at or below
$50,000/LYS and present cost-acceptability curves to
display the results.
Although coronary stenting is not an option for all
patients undergoing percutaneous revascularization,
the large majority are candidates for either PTCA or
stenting. Treating the 4 treatment strategies asmutually
exclusive allowed us to choose the most cost-effective
strategy across a range of threshold values that indicate
the maximum amount of money a decision maker
would pay to gain a statistical life year. To do this, we
computed average net benefits for each strategy29 for
each simulation across a range of threshold values. For
each simulation at each threshold value, 1 strategy is
optimal (greatest net benefits). We plotted the propor-
tionof times each strategywas consideredoptimal. The
resulting curve is intuitively the same as a cost-accept-
ability curve.
Sensitivity Analysis
Because we were starting from the perspective of
conducting an institution-specific CEA and we were
interested in the relative value of considering addi-
tional data sources, we implemented the random-ef-
fects model beginning with data only from UMMS.
Then, we consecutively added information provided
by the trials in order of publication. For clarity, we re-
port only the results of trials involving PTCA with or
without abciximab. After each incremental addition to
the model, we calculated 95% credible intervals and
constructed cost-acceptability curves.
We also explored the effect of different specifica-
tions for the prior distribution using sensitivity analy-
sis. First, we ran all the models without an upper limit
for the event rate so that the MCMC procedure could
sample from all points corresponding to 0% to 100%
event probabilities. Then, we halved the upper limit of
the probability of death (7.6%) and nonfatal MI
(16.1%) to examine the effects of using a less conserva-
tive upper limit for the area of the distribution from
which the MCMC procedure in WinBUGS could sam-
ple.Additional sensitivity analyseswereundertaken to
explore the effect of varying the precision of
hyperpriors for the event probability θ and other pa-
rameters necessary to specify the model, such as the
shape and scale of the γ distribution that contributes to
the amount of variance generated by the model.
Finally, patients in the clinical trials were routinely
monitored for increases in CPK-MB levels to detect
non–Q wave MIs, whereas MIs in the UMMS cohort
were dependent on physician reports of MIs docu-
mented inpatients’medical record.Becausepatients in
routine practice may have been less rigorously moni-
tored for non–Q wave MIs than patients in clinical tri-
als, we believed that we may have underestimated the
incidence of MIs. If theMIs reported in patients’ medi-
cal records primarily reflected Q wave MIs, we be-
lieved thatwemayhave underestimated the number of
MIs in the UMMS cohort by about 400%, given the ra-
tio of QwaveMIs and non–QwaveMIs reported in the
clinical trials. Therefore, we inflated the incidence of
 
MIs at UMMS 4-fold to examine the impact on the
ICERs.
RESULTS
The 100 abciximab-treated patients did not statisti-
cally differ with regard to any of the observed
covariates compared to the 100 matched patients not
treated with abciximab (Table 1). In Table 2, patients
treated at UMMS are stratified by type of percutaneous
revascularization procedure to facilitate comparisons
with patients enrolled in the RCTs. Patients treated at
UMMS were similar to patients treated in the RCTs in
terms of gender, age, hyperlipidemia, and hyperten-
sion (Table 2). However, patients at UMMS were
slightly less likely to have diabetes. Also, patients who
underwent PTCA at UMMS were less likely to have
had previous bypass surgery, reflecting more current
practice patterns inwhich patientswith previous coro-
nary artery bypass grafts aremore likely toundergo cor-
onary stenting.30
Descriptive statistics for the posterior distributions
for death and nonfatal MI at 6 months of followup are
shown in Tables 3 and 4 for each of the RCTs and
UMMS. The means of the posterior distributions were
greater than themedians in all cases, indicating a right-
skeweddistribution.The skewness in theposterior dis-
tributions was in part due to randomMCMC sampling
near the upper limit of θ for the event probabilities
specified in the base casemodel. The credible intervals
for all the distributions were relatively wide.
On the basis of the Monte Carlo simulations of the
decision model, patients treated with stenting plus
abciximab had the highest estimated life expectancy,
13.88 discounted life years, and the highest estimated
costs, $15,379 (Table 5). Angioplasty alone was shown
to have the lowest estimated life expectancy, 13.33 dis-
counted life years. However, the stent-only option was
the least costly, $11,018, on average. On the basis of
point estimates, the angioplasty-only optionwasdomi-
nated by stent-only, being less effective and more
costly.
Themarginal gain in life yearswas 0.26 (3.1months)
with the addition of abciximab to percutaneous inter-
vention (assuming a 50:50 split between PTCA and
stenting) in comparison to percutaneous intervention
without abciximab. A scatterplot displaying the joint
distribution of incremental costs and effectiveness is
shown in Figure 2. The ICER was $13,475/LYS. In
83.4% of the simulations, the addition of abciximab
was more effective than percutaneous revasculariza-
tion without the drug, and in 74% of the simulations,
the ICER was estimated at or below $50,000/LYS
(Fig. 3). Among patients exclusively undergoing PTCA
and coronary stenting, the marginal gains in life years
were about 3.7 months and 3.0 months, respectively,
with the addition of abciximab. These gains translated
to ICERs of approximately $8,000/LYS with PTCA and
$17,500/LYS with stenting. When comparing PTCA
plus abciximab toPTCAalone, 74.1%of the ICERs gen-
eratedwere $50,000/LYS or less.When comparing cor-
onary stenting with abciximab with stenting alone,
Table 1 Comparison of Abciximab-Treated and
Abciximab-Untreated Cohorts at the
University of Maryland Medical System
Abciximab-
Treated Comparison
Cohort Cohort
Characteristic (n = 100) (n = 100) p Valuea
Mean age (y) 57.2 57.6 0.803b
Gender (% male) 72.0 73.0 0.874
Risk factors (%)
Congestive heart failure 9.0 9.0 1.000
Diabetes mellitus 16.0 14.0 0.692
Hyperlipidemia 55.0 58.0 0.669
Hypertension 48.0 54.0 0.396
Indication (%)
Acute MI 12.0 13.0 0.831
Other indication 3.0 3.0 1.000c
Post-MI angina 51.0 45.0 0.396
Stable angina 2.0 1.0 1.000c
Unstable angina 31.0 40.0 0.184
History of previous (%)
CABG 9.0 8.0 0.800
PTCA/stent 10.0 13.0 0.506
Intracoronary thrombus (%) 38.0 35.0 0.659
ACC/AHA morphologyd (%)
A 12.0 10.0 0.651
B1 24.0 27.0 0.626
B2 17.0 19.0 0.713
C 47.0 44.0 0.670
Coronary stenting (%) 50.0 51.0 0.888
Admitted to ICU/CCU (%) 9.0 5.0 0.326
Note: MI = myocardial infarction; CABG = coronary artery bypass graft;
PTCA = percutaneous transluminal coronary angioplasty; ACC = Ameri-
can College of Cardiology; AHA = American Heart Association; ICU = in-
tensive care unit; CCU = cardiac care unit.
a. p value based on Pearson chi-square.
b. p value based on Student’s t test.
c. p value based on Fisher’s exact test.
d. Scoring system based onmorphologic characteristics of the coronary le-
sion used to predict ischemic events. “A” indicates a low-risk lesion, and
“C” indicates a high-risk lesion.
 
66.0% of the simulations were estimated at or below
$50,000/LYS. The other relevant analysiswas the addi-
tion of abciximab to PTCA in comparison to coronary
stenting. The incremental difference in effectiveness
between the strategies was very small (0.005 LYS), re-
sulting in a large ICER ($604,000/LYS) and a relatively
low percentage of simulations (40.0%) in which PTCA
Table 2 Characteristics of Patients from Randomized Clinical Trials and Local Institution
Study
PTCA Stent
UMMS UMMS
EPIC EPILOG PTCA EPISTENT Stent
Characteristic (N = 2099) (N = 2792) (n = 100) (N = 2399) (n = 100)
Male (%) 72 72 74 75 71
Average age (y) 61 60 55 59 60
Risk factors (%)
Diabetes 24 23 14 20 16
Hypertension 55 NR 49 53 53
Hyperlipidemia 57 NR 58 NR 55
Previous CABG (%) 15 13 4 9 13
Procedures (%)
PTCA 95 95a 87 98b 0
Atherectomy 5 6 9 0 0
Rotablator 0 0 4 0 0
Stent 0 14 0 100c 100
Previous MI 57 NR 58 51 62
Note: PTCA= percutaneous transluminal coronary angioplasty; UMMS=University ofMarylandMedical System; NR = not reported; CABG = coronary artery
bypass graft; MI = myocardial infarction.
a. Not mutually exclusive.
b. In the PTCA arm of the trial, 2.3% crossed over to stent.
c. In the stent arm of the trial.
Table 3 Base Case: Incidence of Death at 6 Months
PTCA and abciximab PTCA only
EPIC EPILOG EPISTENT UMMS EPIC EPILOG UMMS
(n = 708) (N = 935) (n = 796) (n = 50) (n = 696) (n = 939) (n = 49)
3.11% 1.07% 1.76% 2.00% 3.45% 1.70% 4.08%
Posterior distribution Posterior distribution
Mean = 1.98% (95% CI = 0.57%–5.00%) Mean = 3.18% (95% CI = 0.67%–9.19%)
Median = 1.72% Median= 2.63%
Stent and abciximab Stent only
EPISTENT UMMS EPISTENT UMMS
(n = 794) (n = 50) (n = 809) (n = 51)
0.50% 0% 1.24% 1.96%
Posterior distribution Posterior distribution
Mean = 0.60% (95% CI = 0.02%–2.99%) Mean = 1.79% (95% CI = 0.20%–7.18%)
Median = 0.32% median = 1.24%
Note: PTCA = percutaneous transluminal coronary angioplasty; UMMS = University of Maryland Medical System; CI = confidence interval.
 
plus angioplasty compared to stenting would be con-
sidered cost-effective at a $50,000/LYS threshold.
The results of thesemodels also allow for the consid-
eration of which of the 4 strategies is optimal for pa-
tients who are candidates for either PTCA or stenting.
When examining the 4 revascularization strategies, the
PTCA option was dominated on the basis of point esti-
mates because itwas less effective andmore costly than
stenting. Using the net benefits approach to examine
each strategy separately (not incrementally) revealed
that at threshold values up to $28,000/LYS, stent only
was considered to be the optimal strategy (Fig. 4). Be-
yond that point, stent plus abciximab was the optimal
strategy in the majority of simulations, followed by
stent only. The strategies involvingPTCAwere optimal
in < 10% of simulations across all threshold values.
Sensitivity Analysis
Increasing the number of data sources included in
the random-effects model led to increased precision in
the 6-month event probabilities. When using only data
from patients who underwent angioplasty plus
abciximab at UMMS, the 95% credible interval for the
incidence of MI ranged from 0.1% to 22.5%, an abso-
lute difference of 22.4 percentage points (Fig. 5). With
the addition of data from the EPIC trial, the credible in-
terval decreased to a range of 19.7 percentage points.
Thewidthof the interval further decreasedwith the ad-
dition of data from EPILOG to 14.9 percentage points,
andwith EPISTENT, the interval decreased to 11.7 per-
centage points. The increased precision in event rates
translated to an increase in the number if simulations
with PTCA plus abciximab were more cost-effective
relative to PTCA alone. At the $50,000/LYS threshold,
the proportion of simulations that showed that PTCA
plus abciximabwas cost-effectivewas 59.2%when us-
ing data from UMMS. With the addition of data from
the 3 clinical trials, this proportion rose to 69.6%.
Sensitivity analyses revealed that the posterior dis-
tributions were sensitive to changes in the upper limit
for the event probability (θ), particularly for the inci-
dence of MI. When we did not specify an upper limit
for θ, the estimated probability of events increased for
all treatment strategies, and the credible intervals were
wider than in the base case (Table 6). Conversely, when
halving the upper limit of θ, the estimated probability
of events decreased for all treatment strategies, and the
Table 4 Base Case: Incidence of MI at 6 Months
PTCA and abciximab PTCA only
EPIC EPILOG EPISTENT UMMS EPIC EPILOG UMMS
(n = 708) (n = 935) (n = 796) (n = 50) (n = 696) (n = 939) (n = 49
6.90% 5.03% 6.53% 4.00% 10.49% 9.90% 2.04%
Posterior distribution Posterior distribution
Mean = 6.08% (95% CI = 2.06%–3.79%) mean = 8.99% (95% CI = 2.16%–21.78%)
Median = 5.47% Median= 7.80%
Stent and abciximab Stent only
EPISTENT UMMS EPISTENT UMMS
(n = 794) (n = 50) (n = 809) (n = 51)
5.16% 2.00% 10.26% 1.96%
Posterior distribution Posterior distribution
Mean = 4.53% (95% CI = 0.42%–16.89%) Mean = 6.76% (95% C I= 5.30%–21.76%)
Median = 3.35% Median= 5.30%
Note:MI =myocardial infarction; PTCA=percutaneous transluminal coronary angioplasty; UMMS=University ofMarylandMedical System; CI = confidence
interval.
Table 5 Baseline Estimates
Treatment/ Average Discounted
Procedure Groups Costa Life Years
Abciximab and stent $15,379 13.88
Abciximab and PTCA $13,898 13.64
Stent only $11,018 13.63
PTCA only $11,432 13.33
Abciximab with 50:50 $14,639 13.76
No abciximab with 50:50 $11,145 13.50
PTCA = percutaneous transluminal coronary angioplasty.
a. In 1998 US dollars.
 
credible intervals were more narrow than in the base
case. Varying the specifications for the precision of θ
and the shape and scale of 1/σ2 had only negligible ef-
fects on the results. Further sensitivity analyses re-
vealed that artificially increasing the incidence ofMI at
UMMS to account for potential differences in reporting
ofMIs increased the estimated posterior average by ap-
proximately 1 to 3 percentage points (Table 6).
Although alteringmodel parameters and event rates
at UMMS led to changes in the posterior distributions,
these adjustments had almost no effect on the relative
cost-effectiveness of the treatment strategies, because
the parameter specifications and data assumptions
were consistently applied across treatment strategies.
The proportion of simulations in which the cost-
effectiveness ratiowas<$50,000/LYSwas73.7%when
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no upper limit for the event probabilities (θ) were
specified, 71.5% when the upper limit was halved,
and 72.8% when the number of MIs at UMMS was
quadrupled.
DISCUSSION
We have shown how the use of propensity scores
can be coupled with a Bayesian statistical approach to
address 2 common limitations of site-specific CEAs: a
lack of randomization and an insufficient sample size.
To accomplish this,we used aBayesian random-effects
model to incorporate site-specific data with clinical
trial results. We then applied the resulting posterior
distributions with local cost data in a traditional
decision-analytic model. The approach provides a
transparent means of integrating data from multiple
sources and produced more precise estimates of cost-
effectiveness, thereby providing locally relevant infor-
mation to formulary decision makers.
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On the basis of our model, our results indicate that
the addition of abciximab is cost-effective at UMMS in
74%of the simulated runs, assuming amaximumwill-
ingness to pay of $50,000/LYS and that approximately
50% of patients undergo coronary stenting and 50%
undergo angioplasty. Sensitivity analyses revealed that
this estimate was robust to changes in the specifica-
tions and assumptions used in the Bayesian model.
Nevertheless, a wide range of cost-effectiveness ratios
were consistent with the data because there was insuf-
ficient evidence to conclude that abciximab-treatedpa-
tients have a longer life expectancy with a high degree
of certainty.
Incorporating evidence from large RCTs decreased
uncertainty in the estimates of cost-effectiveness rela-
tive to the site-specific economic evaluation. In the
base case analysis, the proportion of simulations in
which abciximab was shown to be cost-effective at the
$50,000/LYS threshold was just 74%. Even if one were
willing to spend any amount of money for a gain in life
expectancy, this number would increase to only
83.4%, corresponding with the point at which the
threshold value on the cost-acceptability curve ap-
proaches infinity. However, from a Bayesian decision
theoretical perspective, arbitrary cutoff values for deci-
sion making (such as the commonly employed 5%
level of significance) are irrelevant to decision makers
who must make a choice between 1 intervention and
another.31 Instead, information on uncertainty should
be combined with information about a decision
maker’s loss function, which should include the impli-
cations of making a wrong decision given the number
of potential patients affected and the total number of
dollars involved. Uncertainty then enters the equation
only in the extent to which reducing uncertainty adds
value to the decision maker.32
Our study has several implications for improving
the usefulness of information provided to “real-world”
decisionmakers. First, by considering the combination
of data from clinical trials with local data, it compels
one to directly compare the characteristics of patients
from both sources and to explicitly address observed
differences in those characteristics. In cases in which
onlyminor differences are found, such as in our exam-
ple, it may be appropriate to integrate data from both
sources to obtain more precise estimates of cost-
effectiveness. Another benefit of this exercise that may
occur when minor differences are found is that it can
quell local concerns about the generalizability of the
trial data.However, caremust be employedwhen infer-
ring similarities in treatment effects fromsimilarities in
observed covariates. Although no statistically signifi-
cant differences were found in the observed character-
istics between the UMMS data and that from the RCTs
(see Table 1), Altman33 emphasized that even non-
significant differences in prognostic factors can lead to
influences on the observed outcome.
The approach outlinedhere can be adapted to assess
the likely importance of collecting local data in the first
place, given the extent and availability of randomized
evidence. First, it can allow one to simulate towhat de-
gree patient outcomeswould have to differ between lo-
cal patients and clinical trial patients to have an impact
on the results. Second, our approach could also beused
to determine howmany patients would be needed in a
local evaluation to exert an influence on the clinical
trial results.Althoughour applicationof thesemethods
was limited in that it involved a treatment with a low
incidence of clinical events and one in which large
numbers of patients were enrolled in clinical trials, the
methodswe describe are generalizable to other clinical
situations in which the incidence of events may differ
Table 6 Sensitivity Analysis: Incidence of Myocardial Infarction (MI)
Treatment Four Times Rate of
Strategy Baseline Half Upper Limit No Upper Limit MI at UMMS
PTCA only 8.99%, median = 7.80% 7.96%, median = 7.63% 9.33%, median = 7.98% 10.28%, median = 9.26%
(2.16%–21.78%) (2.13%–14.84%) (2.11-24.21%) (2.95-22.45%)
Stent only 6.76%, median = 5.30% 5.59%, median = 4.81% 7.13%, median = 5.34% 9.8%, median = 8.48%
(0.53%–21.76%) (0.56%–14.14%) (0.59%–25.83%) (1.49%–25.47%)
PTCA and 6.08%, median = 5.47% 5.92%, median = 5.45% 6.11%, median = 5.50% 8.08%, median = 7.31%
abciximab (2.06%–13.79%) (2.23%–12.42%) (2.06%–13.84%) (3.01%–18.01%)
Stent and 4.53%, median = 3.35% 4.12%, median = 3.33% 4.85%, median = 3.42% 7.19%, median = 5.82%
abciximab (0.42%–16.89%) (0.08%–12.15%) (0.43%–18.64%) (1.10%–21.80%)
UMMS = University of Maryland Medical System; PTCA = percutaneous transluminal coronary angioplasty.
 
more substantially between patient groups and in
which there may be fewer patients enrolled in clinical
trials.
Othershavealso explored theuseof aBayesianpara-
digm to increase the generalizability of CEAs.
Rittenhouse34,35 suggestedusing aBayesianapproach to
account for biases in patient selection in RCTs and
other factors such as the detection of subclinical dis-
ease identified through protocol-induced testing. Al-
though our analysis shares the same conceptual basis,
ours differs in that it is the first to use empirical data
from a real-world setting to demonstrate how one can
improve the usefulness of site-specific evaluations by
incorporating clinical trial data when appropriate.
Makingdecisions in ahealth care systemearly in the
life cycle of a new technology is challenging. Current
approaches to performing cost-effectiveness studies
APPENDIX
Code for WinBUGS Model
model
{
# For each of N trials, model the following:
for( i in 1 : N ) {
# b[i] = logit(p[i]), mu, tau defined below
b[i] ~ dnorm(mu,tau)
# p[i] = pr(death in ith trial)
logit(p[i]) <- b[i]
# r[i] = No. of deaths, n[i] = No. of patients in ith trial
r[i] ~ dbin(p[i],n[i])
}
# Hyperpriors:
# mu = logit(θ), taken from a flat, wide normal distribution that cannot take on
# values that equate to a greater than 15% risk of death.
mu ~ dnorm(-3.7,1.0E-5)I(,-1.7)
# tau = 1 / σ2; this distribution prevents extremely large values for
# σ2, while still allowing for a fairly wide range of realistic values.
tau ~ dgamma(2,2)
# Logical nodes of interest: Population mean probability of death theta and
# population standard deviation (on an inverse logit scale) sigma
theta <- exp(mu) / (1 + exp(mu))
sigma <- 1 / sqrt(tau)
}
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